Vascular endothelial growth factor (VEGF-A) antagonists were originally developed to treat cancer, before being used for ocular application in wet age-related macular degeneration (wet AMD).1 Their use in the eye has since expanded, and they are now approved for diabetic macular edema, retinal vein occlusion, plus given off-label for conditions such as neovascular glaucoma. Here, VEGFA is linked to retinal vein occlusion.